pediatrik yaş grubu çeşitli anemik hastalıkların ayırıcı tanısında ...

92. Shimamura A, Guinan CE, Alter PB. Hypoplastic and Aplastic Anemias. In: Nathan
and Oski’s ed. Hematology of İnfancy and Childhood. 6 th ed. W.B Saunders Company,
Philadelphia. 2003; 256-280.
93. Alan D. D’Andrea. The Pancytopenias. Nelson textbook of pediatrics. 17th Edition.
chapter 461: 2004;1642-46.
94. Gaines Das RE, Milne A, Rowley M, Gordon-Smith EC, Cotes PM: Serum
immunoreactive erythropoietin in patients with idiopathic aplastic and Fanconi’s
anaemia. Br J Haematol. 1992; 82:601.
95. Lukens JN. The thalassemias and related disorders: quantitative disorders of
hemoglobin synthesis. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP,
Rodgers GM, ed.Wintrobe's Clinical Hematology, Vol. l .Egypt: William’s and
Williams, trillium. 1999; 1405-1448.
96. Gümrük F, Altay Ç. Talasemiler. Katkı Pediatri Dergisi 1995; 16(3):265-286.
97. Tabbara IA. Hemolytic anemias. The Medical Clinics of North America. 1992;
76(3):663-665.
98. Arcasoy A, Canatan D. Dünyada ve Türkiye’de Talasemiler ve Hemoglobinopatiler.
Arcasoy A. (ed). Hemoglobinopati ve Talasemi Önlem –Tanı –Tedavi 2003.
99. Ağaoğlu L. Kan hastalıkları. Talasemiler In: Neyzi O, Ertuğrul T. Pediatri. Cilt 2. 16.B.
İzmir: Nobel Tıp Kitapevleri; 2002:1059-64.
100. Miyoshi K, KanetoY, Kawai H. X-linked dominant control of cells in normal adult
Life:characterisation of the Swiss type as hereditary persistence of fetal hemoglobin
regulated dominantly by gene(s) on chromosome . Blood 1988,72(6):1854-1860.
101. Craig JE, Rochette J, Fisher CA. Dissecting the loci controlling fetal haemoglobin
production on chromosomes 11p and 6q by the regressive approach. Nat Genet. 1996;
12(1):58-64.
102. Orkin HS, GD Nathan. The Thalassemias. In: Nathan and Oski’s ed. Hematology of
Infancy and Childhood. 6 th ed.Philadelphia,W.B. Saunders company. 2003; 842-921.
103. Özsoylu Ş.Thalassemia Trait or Thalassemia Intermedia.Am.J.Hematol 2001; 67(4)
104. Rund D, Rachmilewitz E. Pathophysiology of alpha- and beta-thalassemia: therapeutic
implications. Semin Hematol 2001; 38(4):343-9.
105. Weatherall DI. The Thalassemias. In: Williams Hematology. Beutler E, Lichtman MA,
Coller BS, Kipps TJ, Seligsohn U, ed. New York, Me Graw- Hill. 2001; 547-580.
106. Onur 0, Sivri A, Gümrük F. Beta thalassaemia: a report of 20 children. Clin Rheumatol
1999;18(1):42-44.
107. Borgna-pignatti C, Rugolotto S, De Stefano P. Survival and disease complications in
thalassemia major. Ann N Y Acad Sci 1998; 850 :227-31.
108. Janka G. Intraveneaus and subcutaneaus desferroxamine therapy in children with severe
iron overload. Europ. J. Pediatr 1981;137-285.
109. Saenger P, Schwartz E, Markenson AL. Depressed serum somatomedin activity in betathalassemia.
J Pediatr 1980; 96(2):214-8.
110. Grundy RE, Woods KA, Savage MO. Relationship of endocrinopathy to iron chelation
status in young patients with thalassaemia major. Arch Dis Child 1994; 71(2):128-32.
111. Anapliotou ML, Kastanias IT, Psara P. The contribution of hypogonadism to the
development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin
Endocrinol (Oxf) 1995; 42(3):279-87.
107